Vivoryon Therapeutics N.V. (LON:0R3M)

Market Cap	28.29M -24.2%
Revenue (ttm)	n/a
Net Income	-5.83M
EPS	-0.20
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,006
Open	1.115
Previous Close	1.110
Day's Range	1.095 - 1.115
52-Week Range	1.020 - 1.820
Beta	1.44
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 7, 2026

About Vivoryon Therapeutics

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 13
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R3M

Financial Performance

Financial numbers in EUR

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 25, 2026

Data Sources Report a data error